Plain-English translation of NCT04654338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new approach to treating early-stage prostate cancer by combining two types of focused radiation therapy in quick succession. The first treatment, called stereotactic ablative body radiation (SABR), delivers a high dose of radiation to the entire prostate in a single session. About two to three weeks later, patients receive a second radiation treatment called high-dose-rate brachytherapy, which places radiation directly inside the prostate. The goal is to destroy cancer cells while minimizing damage to surrounding healthy tissue and reducing long-term side effects.
Most prostate cancer treatments require many weeks of radiation or involve surgery with significant recovery time and potential complications. This trial explores whether combining two shorter, highly focused radiation treatments might be more effective and easier on patients than traditional approaches.
You likely qualify if…
You likely don't qualify if…
You will have imaging scans and a biopsy before treatment begins. Your first radiation treatment (SABR) occurs about two weeks later, delivered in a single session using a specialized machine. Approximately one to three weeks after that, you receive your second radiation treatment (brachytherapy) as a single session. After treatment, you will have follow-up visits at 6, 12, and 24 weeks, then at various intervals up to five years. During these visits, you'll have blood tests, answer questionnaires about your symptoms and quality of life, and be monitored for any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Canada